arrow
R

Rocco Spagnuolo

Magna Graecia University
H指数:22
被引数:2,673

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease—A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD)

真实世界中乌帕替尼在克罗恩病患者中的有效性和安全性——一项来自意大利炎症性肠病研究组(IG-IBD)的多中心前瞻性研究

2026-09-110
PRE
Upadacitinib’s Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study

乌帕替尼作为溃疡性结肠炎患者二线或三线治疗的有效性与安全性:真实世界研究数据

2025-11-030
OAAI
Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study

Tursi, A.; Mocci, G.; Costa, F.; Ceccarelli, L.; Savarino, E.; De Barba, C.; Mucherino, C.; D’antonio, E.; Montesano, L.; Marzo, M.; 等. Filgotinib 在溃疡性结肠炎患者中作为二线或三线治疗的有效性与安全性:真实世界研究数据. Intest. Res. 2025, 已接收. [CrossRef] [PubMed]

2025-09-011
PRE
Rational optimization of D3R/GSK-3β dual target-directed ligands as potential treatment for bipolar disorder: Design, synthesis, X-ray crystallography, molecular dynamics simulations, in vitro ADME, and in vivo pharmacokinetic studies

基于理性的D3R/GSK-3β双靶点导向配体的优化及其作为双相情感障碍潜在治疗药物的研究:设计、合成、X射线晶体学、分子动力学模拟、体外ADME及体内药代动力学研究

2025-06-250
PRE
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning—the IG-IBD LIVE study

Vedolizumab在炎症性肠病中的真实世界结局及其机器学习预测——IG-IBD LIVE研究

2025-05-120
PRE
P0634 Upadacitinib Effectiveness And Safety In Patients With Ulcerative Colitis: Data From A Real-World Study
2025-01-220
PRE
Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study
2025-01-220
PRE
Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study
2024-11-271
OAAI
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium
2024-07-010
OAAI
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study
2024-01-256
PRE